Us TOO Presents: Prostate Cancer Pathways
Video Recorded on October 12, 2019
In Detroit, MI
As a Featured Presentation at: Karmanos Cancer Institute Cancer Symposium 2019
With Presenting Experts:
- Zachery Roger Reichert MD, PhD – Medical Oncologist
- Shelley L. Imholte, PhD, LCSW, M.Ed. – Sexual Life Improvement
- Bahaa S. Malaeb, MD, FACS – Associate Professor, Genitourinary Trauma and Reconstructive Surgery; Medical Director, Taubman Urology Ambulatory Care Unit, University of Michigan
- Gary McClain PhD, LMHC, CEAP – Counselor
CLICK TIME FOR DIRECT LINK TO EACH SEGMENT BELOW
- 0:01 Intro – Joel Nowak, Co-Founder Cancer ABCs
- 1:41 About Prostate Cancer – Dr. Zachery Reichert
- 3:06 Balance of Cancer Care – Risk and Benefit
- 6:01 Prostate Cancer Phases
- 6:13 Clinically Localized Disease
- 6:35 Rising PSA, Biochemical Recurrent Prostate Cancer
- 7:22 Metastatic Hormone/Castration-Sensitive Prostate Cancer (mHSPC)
- 7:59 Non-Metastatic Hormone/Castration-Reistant Prostate Cancer (nmCRPC)
- 9:03 Metastatic Hormone Resistant Disease (mcRPC) – Treatments 1 and 2
- 10:51 Testosterone (the Fuel for Prostate Cancer)
- 11:16 Low Testosterone
- 13:19 Sexual Dysfunction, Importance of Communication
- 15:00 Imaging and Scanning
- 15:50 PSMA (Prostate Specific Membrane Antigen) Based PET Scan
- 18:11 Clinically Localized Prostate Cancer
- 18:22 Active Surveillance
- 19:12 Surgery
- 19:41 Radiation
- 20:08 Rising PSA After Local Therapy – Biochemical Recurrence
- 20:17 Monitoring
- 20:27 Salvage Radiation
- 20:37 Hormone Therapy
- 20:50 Risk and Benefit of Monitoring and Hormone Therapy
- 21:15 No Metastases, Low Testosterone, Hormone Resistance (nmCRPC) – Rising PSA
- 21:31 Continue Testosterone Lowering Therapy
- 21:59 Treatments (Enzalutamide, Apalutamide, Darolutamide)
- 22:25 Metastases with Intact Testosterone (nHSPC)
- 22:41 Start Testosterone Lowering Therapy
- 23:02 Intensification Strategy (Docetaxel, Abiraterone, Apalutamide)
- 23:31 New Metastases with Low Testosterone (mCRPC)
- 23:47 Continue Testosterone Lowering Therapy
- 23:55 Additional Treatment Options (Docetaxel, Cabazitaxel, Abiraterone, Prednisone, Enzalutamide, Radiation, Sipuleucel-T)
- 24:57 Future – Prevision Medicine, PSMA Based Therapy
- 27:00 Cancer is a Prairie, Not a Corn Field
- 28:40 Discussion/Q&A from a Patient Perspective
- 28:55 Shared Decision Making
- 31:49 Monitoring
- 33:57 Importance of Bone Health
- 43:01 PSA and Immunotherapy
- 46:06 Thanks to Sponsors – Chuck Strand, CEO of Us TOO International
- 47:30 Panel Intro by Jim Schraidt, Chairman of the Board of Us TOO International
- 50:17 Panel Introduction – Dr. Bahaa S. Malaeb, Gary McClain, Dr. Shelley L. Imholte
- 51:15 Jim Schraidt's Story – Diagnosis, Depression, Support Group
- 53:01 Gary McClain's Story – Background, Emotions Related to Diagnosis, Depression and Anxiety
- 57:48 Gary McClain – Advice for the Newly Diagnosed on Symptoms of Depression
- 59:09 Dr. Malaeb – Informed Patient Decisions, Treatment Options and Side Effects
- 1:03:28 Dr. Imholte – Sexual Dysfuction
- 1:06:39 Dr. Imholte – Recommendations for Couples on Communication, Titration
- 1:10:48 Q&A
- 1:10:57 How Can a Support Group Leader Help Men with Symptoms of Depression?
- 1:15:15 What if diagnosed, with no symptoms, and you do nothing to treat to avoid side effects?
- 1:21:10 Testosterone – Sexual Function and Effects of Hormone Treatment
- 1:25:32 Risk Factors for and Contributors to Prostate Cancer
- 1:28:03 Support to Address Fatigue, Deficiencies, Depression During Treatment
Thank You to Host: Karmanos Cancer Institute and Sponsors: Astellas, Pfizer Oncology, Janssen Oncology, Amgen, Clovis Oncology, Dendreon, Genomic Health, Timm Medical Technologies Inc., and Advanced Accelerator Applications.